Comparative Pharmacology
Head-to-head clinical analysis: CEFMAX versus CEFTAROLINE FOSAMIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFMAX versus CEFTAROLINE FOSAMIL.
CEFMAX vs CEFTAROLINE FOSAMIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CEFMAX (cefepime) is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 in Gram-negative bacteria and PBP-1a/1b in Gram-positive bacteria, thereby disrupting peptidoglycan cross-linking and leading to cell lysis. It has zwitterionic properties facilitating rapid penetration through Gram-negative outer membranes and is relatively resistant to hydrolysis by many beta-lactamases, including AmpC beta-lactamases.
Ceftaroline fosamil is a prodrug that is converted to the active metabolite ceftaroline. Ceftaroline inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in MRSA and PBP2x in Streptococcus pneumoniae, thereby preventing cross-linking of peptidoglycan.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
600 mg IV every 12 hours infused over 1 hour
None Documented
None Documented
2–4 hours in adults with normal renal function; prolonged to 20–40 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life is approximately 2.6 hours in patients with normal renal function. This supports twice-daily dosing in most infections.
Primarily renal (80–90% unchanged via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for <5%.
Renal excretion of unchanged ceftaroline accounts for approximately 88% of the administered dose. Biliary/fecal elimination is minimal (<6%).
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic